A daily snack that combines oat β-glucan (3 g) with plant sterols (2 g) lowered “bad” cholesterol more than either ingredient alone in over just 6 weeks.

Objective
Evaluate whether combining high–molecular-weight oat β-glucan (OBG; 3 g/day) with phytosterols (PS; 2 g/day) produces greater lipid-lowering than either component alone in adults with hypercholesterolemia.

Methods

• Double-blind, placebo-controlled, 2×2 factorial RCT (four parallel arms; 6 weeks). 
• Participants (free-living adults with elevated TC/LDL-C; n=72 analyzed, 18/arm) consumed eight snack biscuits/day formulated to deliver: Placebo (PL); PS (2 g/day); OBG (3 g/day; MW ~2,000–2,500 kDa; high viscosity); or PS+OBG. 
• Macronutrients were matched across products; all biscuits had identical sensory characteristics and contained ~30 g fat/serving to standardize the lipid matrix. 
• Participants were instructed to take biscuits with ≥250 mL fluid to enhance OBG viscosity. 
• Primary endpoint: total cholesterol (TC); secondary endpoints: LDL-C, HDL-C, TG, TC:HDL-C. 
• Fasting labs at baseline and week 6; compliance by logs and pack counts. 
• Statistical plan included within-arm changes, between-arm contrasts, two-way ANOVA main effects (PS, OBG) and interaction, and covariate-adjusted models. 

Results

• TC (primary): Mean reductions from baseline: PS −4.6%, OBG −5.7%, PS+OBG −11.5% (all significant within arms). PS+OBG lowered TC more than PL and PS (between-arm).
• LDL-C: Mean reductions: PS −7.6%, OBG −8.6%, PS+OBG −13.9% (all significant within arms). PS+OBG < PL between-arm; differences vs PS or OBG alone were not significant.
• TC:HDL-C ratio: Reduced 8.9% within PS+OBG; no between-arm differences.
• TG: −8.4% in PS+OBG (NS overall); exploratory split suggested larger TG falls among those with baseline TG ≥1.7 mmol/L (Fig 3, p. 8), but the study was not powered for TG.
• HDL-C: No change.
• Additivity vs synergy: Two-way ANOVA showed main effects for PS and OBG on TC (and for OBG on LDL-C) with no PS×OBG interaction, indicating additive rather than synergistic action.
• Tolerability/safety: Excellent compliance (~98%), identical sensory experience, and good tolerability; one discontinuation for biscuit intolerance; no clinical safety signals.

Interpretation
Over 6 weeks, high-MW, high-viscosity OBG (3 g/day) and PS (2 g/day) each lowered TC/LDL-C, and their combination produced the largest TC and LDL-C reductions, consistent with additive mechanisms. Effects on TG were inconclusive overall but may be greater in individuals with higher baseline TG.

Mechanisms & pathways (discussed by authors)

• OBG (1,3/1,4-β-glucan): Viscosity-driven increase in luminal thickness reduces bile-acid reabsorption, increasing fecal bile loss and stimulating hepatic bile-acid synthesis (increased 7α-hydroxy-4-cholesten-3-one; increasedCYP7A1) and LDL-receptor upregulation, thereby lowering circulating LDL-C. High molecular weight is critical to viscosity and efficacy; processing that lowers MW diminishes effect.
• PS: Micellar displacement of cholesterol in the gut, reducing absorption; minimal systemic PS uptake due to ABCG5/ABCG8 efflux.

Combined, these act at complementary intestinal targets (micellar cholesterol vs bile-acid reabsorption).

Dosages & adverse reactions

• Dose/formulation: OBG 3 g/day (MW ~2,000–2,500 kDa) and/or PS 2 g/day, delivered in one daily biscuit serving as a snack for 6 weeks; instructed to co-ingest ≥250 mL fluid.
• Adverse reactions: Overall well tolerated; no consistent adverse event pattern reported; one discontinuation due to intolerance of biscuits.

Quality of study (assessment)
Strengths: Rigorous double-blind, placebo-controlled, factorial RCT; clearly characterized high-MW OBG; matched products; strong compliance.
Limitations: Short duration (6 weeks); LDL-C estimated (Friedewald); no mechanistic biomarkers in vivo (bile acids, fecal sterols, viscosity); snack-time dosing may differ from meal-time physiology; not powered for TG; modest baseline imbalances in anthropometrics (addressed statistically).

Implications
For adults with hypercholesterolemia who are diet-managing or statin-intolerant, a food-based regimen providing OBG ~3 g/day (high MW, high viscosity) plus PS ~2 g/day can deliver additive LDL-C and TC lowering within weeks, with good tolerability. Clinically, prioritize verified high-MW β-glucan and adequate fluid co-ingestion; consider baseline TG when targeting triglyceride responses; and counsel that benefits require continued intake.